Regulation - Stivarga


Current filters:


Popular Filters

Bayer files for EU approval of regorafenib for GIST


German pharma major Bayer (BAYN: DE) said this morning (September 5) that it has submitted an application…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationStivarga

Bayer and Onyx' Stivarga cleared in Europe


In a second piece of good news within a couple of days for German drug major Bayer (BAYN: DE), the European…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

Bayer gets Japanese OK for GI stromal tumors drug


German drug major Bayer (BAYN: DE) has received approval from the Ministry of Health, Labor and Welfare…


FDA expands use of Bayer and Onyx' Stivarga for advanced GIST


The US Food and Drug Administration yesterday expanded the approved use of German drug major Bayer's…

BayerNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

News briefs: Bayer's Stivarga and AstraZeneca's Faslodex


German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

Early FDA approval for Bayer's Stivarga in advanced colorectal cancer


Bayer said Stivarga will be ready for distribution as soon as today (September 28 and set a wholesale…

BayerNorth AmericaOncologyPharmaceuticalregorafenibRegulationStivarga

Back to top